Stock screenerAll disclosures →
EDGAR →
KYTX
Conviction 24HealthcareScan · Thu, Sep 24, 2026Kyverna Therapeutics, Inc. (KYTX) closed at $7.01 (-0.85%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 39, RS Rating 46, -37.7% from its 52-week high, -20.1% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).
KYTX$7.01-0.85%
ResistanceSupportVol 14Vol MA14 1.04M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price7.01
Change-0.85%
Gap+10.40%
Rel volume6.22×
Avg volume947.85K
Avg $ vol7.11M
SMA 207.68
SMA 507.80
SMA 2008.42
Price vs 50-10.11%
Price vs 200-16.73%
MA stackbearish
50/200 cross—
Supertrenddown · 8.26
RSI (14)39
MACD hist-0.05
MACD cross—
Stoch %K / %D20 / 22
ADX (14)21
+DI / −DI19 / 19
RSI divergence—
MACD divergence—
ATR %6.84%
ADR %5.46%
52w high11.25
52w low5.41
From 52w high-37.69%
Above 52w low+29.57%
New 52w highNo
SqueezeOff
Bollinger width32.22%
%B0.23
Donchian pos15.86%
Donchian high8.79
Donchian low6.68
AVWAP (52w high)8.66
vs AVWAP high-19.09%
AVWAP (52w low)8.46
vs AVWAP low-17.12%
OBV trendDown
Chaikin MF (20)-0.20
Today vs 20d6.22×
Avg vol (14d)1.04M
Avg vol (20d)947.85K
Avg $ vol (20d)7.11M
Market cap433.52M
RS Rating46 / 99
RS 3m (vs SPY)-19.00%
RS 6m (vs SPY)-27.74%
RS line new highNo
Trend template1/8
Technical rank19.6
1 week-0.43%
1 month-20.70%
3 months-14.51%
6 months-10.93%
1 year+11.09%
YTD-20.07%
P/E-2.69
P/B2.62
P/S—
P/FCF-2.82
EPS-3.64
Div yield—
ROE-97.44%
ROA-73.38%
Debt/Eq0.15
Current9.06
EV/EBITDA-2.54
Gross margin—
Net margin—
Rev growth—
EPS growth-26.54%
Price target30.33
Target upside332.67%
Analyst ratingBuy
Institutional71.12%
Ent. value426.6M
Revenue—
Net income-38.32M
Gross profit—
Free cash flow-153.72M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out60.8M
Employees129
ListedThu, Feb 8, 2024
Free float35.7M
Float %59.1%
Short interest8.45M
Days to cover12.3d
Short volume73.5%
Squeeze score100 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.63 vs −$0.67
Last surprise+6.0% beat
Setup gradeD
Conviction24 / 100
Pattern quality—
Tech rank19.6 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance9.01
Support6.98
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Kyverna Reports One-Year Miv-Cel Data From SPS and gMG TrialsAdvfn · Thu, Sep 24, 2026
- Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia GravisYahoo Finance · Thu, Sep 24, 2026
Congress activity
Disclosed STOCK Act trades in KYTX
No recent disclosed trades by Congress in KYTX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in KYTX
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
CLARK IAN T Director · Stock Option (right to buy) · 2026-05-27 | Grant | 20.58K | $0 | 2026-05-27 | 2026-05-29 |
SEIDENBERG BETH C Director · Stock Option (right to buy) · 2026-05-27 | Grant | 20.58K | $0 | 2026-05-27 | 2026-05-29 |
Cohen Fred E Director · Common Stock · 2026-05-27 | Grant | 5.09K | $0 | 2026-05-27 | 2026-05-29 |
Shaw Christi Executive Chairperson · Common Stock · 2026-05-27 | Tax | 4.19K | $36K | 2026-05-27 | 2026-05-29 |
Aktar Mert Director · Common Stock · 2026-05-27 | Grant | 5.09K | $0 | 2026-05-27 | 2026-05-29 |
Cohen Fred E Director · Common Stock · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-29 |
SEIDENBERG BETH C Director · Common Stock · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-29 |
Cohen Fred E Director · Stock Option (right to buy) · 2026-05-27 | Grant | 20.58K | $0 | 2026-05-27 | 2026-05-29 |
Aktar Mert Director · Stock Option (right to buy) · 2026-05-27 | Grant | 20.58K | $0 | 2026-05-27 | 2026-05-29 |
CLARK IAN T Director · Common Stock · 2026-05-27 | Grant | 5.09K | $0 | 2026-05-27 | 2026-05-29 |
SEC filings
EDGAR filings in KYTX · 7 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.